GentiBio champions build-a-Treg approach with $157M series A

With the burgeoning Treg space largely split into two camps, GentiBio Inc. has raised nine-figure funding in support of the hypothesis that T cells forced to express FOXP3 will outperform Tregs born that way, with an assist from a synthetic source of IL-2 signaling.

The Boston-based engineered Treg newco is using its $157 million series A led by Matrix Capital Management to build its own GMP manufacturing infrastructure in Seattle; last week, Sonoma Biotherapeutics also announced it would be using its $265 million series B round to culture the notoriously difficult cell type in-house...